HEMATHERIX LLC

La Jolla, CA · Biotech · Private

SuperFVa, an engineered activated factor V protein resistant to inactivation by activated protein C, for treating acute traumatic coagulopathy

Grants
$590K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Prevention and mitigation of acute traumatic coagulopathy and bleeding$295,000
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Prevention and mitigation of acute traumatic coagulopathy and bleeding$295,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2259KARAMEDICA, INC.——
2260Origin Speech Therapy Inc.—$2.6M
2261TRAMPOLINE PHARMA, INC.——
2262HEMATHERIX LLC——
2263TACIT THERAPEUTICS, INC.——
2264SOTERIA SYSTEMS, INC.—$2.7M
2265LineaGen, Inc—$38M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.